Related by context. All words. (Click for frequent words.) 77 relapsing remitting multiple sclerosis 67 relapsing remitting MS 66 PEGylated interferon beta 1a 65 recurrent glioblastoma multiforme 64 COPAXONE R 63 relapsing multiple sclerosis 63 Laquinimod 62 relapsed refractory multiple myeloma 62 relapsing remitting MS RRMS 62 RRMS patients 62 laquinimod 62 COPAXONE ® 62 Relapsing Remitting Multiple Sclerosis 61 PsA 61 lymphoma CTCL 61 metastatic renal cell carcinoma 60 relapsing MS 60 recurrent glioblastoma 60 AVONEX ® 60 BRIM2 59 relapsing remitting 59 relapsed multiple myeloma 59 ACTEMRA TM 59 immunomodulatory therapy 59 mRCC 59 lupus nephritis 59 teriflunomide 59 adult chronic ITP 59 Adalimumab 59 ankylosing spondylitis AS 59 arthritis PsA 59 stage IIIB 58 Diabetic Macular Edema 58 SJIA 58 idiopathic Parkinson disease 58 bendamustine 58 leukemia AML 58 phase IIa clinical 58 vandetanib 58 phase IIb clinical 58 Acute Coronary Syndromes ACS 58 systemic lupus erythematosus SLE 58 cutaneous T cell 58 relapsed MM 58 IBS C 58 refractory multiple myeloma 58 crizotinib PF # 58 sunitinib malate 58 mTOR inhibitor 58 systemic lupus erythematosus 58 leukemia CLL 58 ponatinib 58 HER2 positive metastatic breast 58 non metastatic osteosarcoma 58 progressive PsA 58 antibody MAb 57 Alemtuzumab 57 eculizumab 57 recurrent NSCLC 57 chronic ITP patients 57 AGILECT ® 57 tanespimycin 57 PEGINTRON TM 57 superficial bladder cancer 57 Aflibercept 57 partial onset seizures 57 Chronic Myeloid Leukemia 57 recurrent GBM 57 ACTEMRA 57 RoACTEMRA 57 Rheumatoid Arthritis RA 57 sJIA 57 IV NSCLC 57 hypoparathyroidism 57 ADHF 57 heavily pretreated 57 hepatocellular carcinoma HCC 57 active ankylosing spondylitis 57 placebo controlled clinical 57 YONDELIS 57 ZOLINZA 57 glioblastoma multiforme GBM 57 relapsing forms 57 acute ischemic stroke 57 pomalidomide 57 AGILECT R 57 evaluating tivozanib 57 Sapacitabine 57 metastatic HRPC 57 beta 1a 57 biologic therapy 57 tocilizumab 57 diabetic neuropathic pain 57 HeFH 57 forodesine 57 juvenile idiopathic arthritis 57 relapsed CLL 57 refractory AML 56 Golimumab 56 AA Amyloidosis 56 PD LID 56 leukemia ALL 56 glatiramer acetate 56 Amrubicin 56 Catena ® 56 post herpetic neuralgia PHN 56 MabCampath 56 Tocilizumab 56 unstable angina UA 56 desvenlafaxine succinate 56 hypercalcemia 56 receptor tyrosine kinase inhibitor 56 acute myelogenous leukemia AML 56 follicular NHL 56 Myelodysplastic Syndrome MDS 56 Systemic Juvenile Idiopathic 56 Doxil ® 56 myelodysplastic syndrome MDS 56 alemtuzumab Campath 56 Etanercept 56 PRTX 56 Rilonacept 56 oral FTY# 56 chronic lymphocytic leukemia CLL 56 CYT# potent vascular disrupting 56 acute coronary syndrome 56 Relapsing remitting MS 56 SUTENT 56 opioid induced bowel dysfunction 56 lumiliximab 56 refractory metastatic colorectal cancer 56 neurogenic orthostatic hypotension 56 CIMZIA TM certolizumab pegol 56 VELCADE melphalan 56 prostate cancer HRPC 56 anterior uveitis 56 eosinophilic asthma 56 relapsed ovarian cancer 56 metastatic RCC 56 immune thrombocytopenic purpura ITP 56 noninfectious uveitis 56 Cimzia ® 56 cell lymphoma CTCL 56 HuMax EGFr 56 interferon beta therapy 56 CIMZIA ™ 56 acute coronary syndromes ACS 56 LUMINATE 56 opioid induced constipation OIC 56 relapsed refractory 56 ischemic cardiomyopathy 56 metastatic hormone refractory 56 atypical Hemolytic Uremic Syndrome 56 refractory NSCLC 56 indolent NHL 56 aHUS 56 diabetic gastroparesis 56 fibromyalgia syndrome 56 pseudobulbar affect PBA 55 antiepileptic drug 55 ulcerative colitis UC 55 hematological malignancy 55 diabetic macular edema DME 55 demyelinating 55 Natalizumab 55 AFib 55 somatostatin analog 55 advanced hepatocellular carcinoma 55 autoantibody positive 55 antiarrhythmic drug 55 cilengitide 55 Crohn disease 55 DPNP 55 SEROQUEL 55 alemtuzumab treated 55 metastatic malignant 55 anti TNF 55 HuMax CD4 55 Phase Ib clinical 55 myelofibrosis 55 sunitinib 55 Aryplase 55 painful diabetic neuropathy 55 Cutaneous T 55 Cladribine Tablets 55 sorafenib tablets 55 Gleevec resistant 55 fistulizing Crohn disease 55 alvespimycin 55 disease modifying 55 APTIVUS r 55 Acute Myelogenous Leukemia AML 55 biliary tract cancer 55 Systemic Lupus Erythematosus SLE 55 pediatric Crohn disease 55 Raptiva R 55 BAY #-# 55 ACZ# 55 nab paclitaxel 55 refractory colorectal cancer 55 IFN beta 55 vidofludimus 55 lacosamide 55 Hepatocellular Carcinoma HCC 55 cutaneous T 55 paroxysmal atrial fibrillation 55 romidepsin 55 relapsed Hodgkin lymphoma 55 Xanafide 55 mg administered orally 55 castration resistant prostate cancer 55 T2DM 55 chronic myeloid leukemia CML 55 metastatic GIST 55 CIMZIA TM 55 Diabetic Macular Edema DME 55 Primary IGFD 55 stable angina 55 rheumatoid arthritis RA 55 NP2 Enkephalin 55 INCB# [003] 55 registrational trial 55 bosentan 55 Cimzia ® certolizumab pegol 55 INCB# [001] 55 unresectable malignant mesothelioma UMM 55 MIRAPEX ER 55 Neovascular AMD 54 dacarbazine 54 rilonacept 54 CHOP chemotherapy 54 secondary hyperparathyroidism 54 acute leukemias 54 LUX Lung 54 pancreatic NET 54 chronic eosinophilic leukemia 54 diagnosed multiple myeloma 54 REMICADE ® 54 Traficet EN 54 CCX# B 54 VAPRISOL 54 Relapsing Remitting MS 54 proliferative diabetic retinopathy 54 metastatic renal cell 54 unresectable stage 54 medullary thyroid cancer 54 Acute Myeloid Leukemia AML 54 relapsed AML 54 chlorambucil 54 Degarelix 54 metastatic colorectal carcinoma 54 Behcet disease 54 NMIBC 54 retinal vein occlusion 54 schizophrenia CIAS 54 Alzhemed TM 54 Ambrisentan 54 Safinamide 54 NATRECOR R 54 KRAS mutations occur 54 TMC# C# 54 gastrointestinal stromal tumors GIST 54 smoldering multiple myeloma 54 basal cell carcinoma BCC 54 Cimzia TM 54 Restless Legs Syndrome RLS 54 symptomatic BPH 54 PSVT 54 de novo kidney transplant 54 metastatic malignant melanoma 54 Tyrima 54 melphalan prednisone 54 Bronchiectasis 54 CIPN 54 refractory CTCL 54 SPRYCEL ® 54 opioid induced constipation 54 riociguat 54 MGd 54 Leber Hereditary Optic Neuropathy 54 rheumatoid arthritis RA psoriatic 54 systemic ALCL 54 imatinib mesylate Gleevec 54 dasatinib Sprycel ® 54 Telintra 54 Hodgkin lymphoma HL 54 Myelofibrosis 54 juvenile idiopathic arthritis JIA 54 desvenlafaxine 54 Parkinson disease PD 54 ruboxistaurin 54 pancreatic neuroendocrine tumors 54 Phase 2b clinical 54 relapsed SCLC 54 partial onset 54 Keppra ® 54 refractory cutaneous T 54 unresectable locally advanced 54 BENICAR 54 imatinib resistant 54 histone deacetylase HDAC inhibitor 54 malignant pleural mesothelioma 54 refractory CLL 54 dasatinib 54 fosbretabulin 54 SHPT 54 NSCLC 54 chronic myocardial ischemia 54 castrate resistant prostate cancer 54 investigational compound 54 mildly symptomatic 54 multicentre randomized 54 metastatic bladder 54 vascular disrupting agent 54 mCRC 54 rituximab refractory 54 Phase Ib II 54 regorafenib 54 alefacept 54 Ph + ALL 54 acute migraine 54 MELAS 54 orally inhaled migraine 54 bone metastases 54 Genasense ® 54 Vimpat ® 54 hypereosinophilic syndrome 54 Acute Decompensated Heart Failure 54 Tavocept 54 metastatic CRC 54 galiximab 54 acute GvHD 54 IRESSA 54 panitumumab Vectibix 54 GW# [003] 54 ofatumumab 54 adalimumab 54 APTIVUS R 53 Chronic Myelogenous Leukemia CML 53 TNF alpha inhibitor 53 pertuzumab 53 primary hypercholesterolemia 53 risperidone Risperdal 53 Fingolimod 53 Dalbavancin 53 adalimumab Humira 53 Voreloxin 53 SEROQUEL XR 53 rufinamide 53 OncoVEX GM CSF 53 rheumatoid arthritis psoriatic arthritis 53 Lupus Nephritis 53 recurrent ovarian cancer 53 COPAXONE 53 pulmonary hypertension PH 53 glatiramer acetate GA 53 thetreatment 53 differentiated thyroid 53 Mitoxantrone 53 Fx #A 53 blinded randomized placebo controlled 53 carboplatin paclitaxel 53 annualized relapse 53 Tarceva TM 53 atherothrombotic events 53 brain metastases 53 Angiox R 53 Vaprisol 53 dopamine partial agonist 53 mitoxantrone plus 53 double blinded placebo 53 CYPHER Stent 53 tafamidis 53 dasatinib Sprycel 53 Chronic Heart Failure 53 hepatic encephalopathy 53 Zavesca ® 53 active comparator 53 neuropsychiatric symptoms 53 teduglutide 53 atrial fibrillation AF 53 resectable 53 systemic juvenile idiopathic 53 Teriflunomide 53 romiplostim 53 PREZISTA r 53 TMS Therapy 53 cetuximab Erbitux R 53 FOLPI 53 Daclizumab 53 Scale EDSS 53 diarrhea predominant irritable 53 dose escalation clinical 53 unresectable 53 systemic anaplastic large 53 prodromal symptoms 53 oropharyngeal candidiasis 53 NeuroStar TMS Therapy 53 Avonex interferon beta 1a 53 Akt inhibitor 53 Lu AA# 53 primary immunodeficiency PI 53 Diffuse Large B 53 uveitis 53 TEMODAL 53 cetuximab Erbitux ® 53 Dasatinib 53 FOLFIRI 53 proliferative retinopathy 53 dirucotide 53 Panzem R NCD 53 colorectal liver metastases 53 LEUKINE 53 6R BH4 53 imatinib Gleevec ® 53 tumor lysis syndrome 53 familial amyloidotic polyneuropathy FAP 53 axitinib 53 sorafenib Nexavar ® 53 Evoltra ® 53 C1 INH deficiency 53 Certolizumab pegol 53 gout flares 53 psoriatic arthritis PsA 53 dirucotide MBP# 53 TTF Therapy 53 Pixantrone 53 medically refractory 53 CTCL 53 nilotinib 53 REMINYL ® 53 ARICEPT 53 post herpetic neuralgia 53 Tolvaptan 53 mCRC patients 53 relapsed leukemia 53 metastatic carcinoid 53 constipation OIC 53 HUMIRA 53 NYHA Class II 53 randomized multicenter 53 docetaxel Taxotere R 53 Rotigotine 53 MERLIN TIMI 53 Phase 1b clinical 53 Pharmacokinetics PK 53 Severe Primary IGFD 53 gastrointestinal stromal tumor GIST 53 assessing T DM1 53 cisplatin chemotherapy 53 abatacept 53 paroxysmal AF 53 omacetaxine mepesuccinate 53 Gastrointestinal Stromal Tumors 53 homozygous familial hypercholesterolemia 53 Chronic Fatigue Syndrome CFS 53 ximelagatran 53 vemurafenib 53 IV metastatic melanoma 53 rotigotine transdermal patch 53 plus gemcitabine 53 etanercept 53 situ CIS 53 severe idiopathic Restless 53 Wet AMD 53 cediranib 53 neovascular diseases 53 recurrent malignant glioma 53 visilizumab 53 oral rivaroxaban 53 lenalidomide dexamethasone 53 chronic plaque psoriasis 53 nonmetastatic prostate cancer 53 virus HCV infection 53 Chronic Myeloid Leukemia CML 53 systemic sclerosis 53 refractory APL 53 Interferon beta 1a 53 vismodegib 53 erlotinib Tarceva ® 53 metastatic pancreatic 53 metastatic castration resistant 53 invasive candidiasis 53 non splenectomized 53 vinorelbine 53 non squamous NSCLC 53 ThermoDox ® 53 Intervention Effectiveness 53 Mipomersen 53 Omacetaxine 53 CRVO 53 Herceptin trastuzumab 53 acute myocardial infarction AMI 53 gefitinib Iressa 53 RAPTIVA 52 oral ridaforolimus 52 elotuzumab 52 BRAF inhibitor 52 antiangiogenic agent 52 pediatric malignancies 52 DMARD therapy 52 FAMPYRA 52 sorafenib Nexavar 52 multiple myeloma MM 52 claudication 52 Quinamed 52 Gleevec Glivec 52 efalizumab 52 Ophena TM 52 B CLL 52 SNT MC# 52 previously untreated follicular 52 anti leukemic 52 myelofibrosis MF 52 Romidepsin 52 Glioblastoma Multiforme 52 Romiplostim 52 Phenoptin 52 TYZEKA 52 ceftazidime 52 advanced metastatic renal 52 Valdoxan 52 Cell Lymphoma 52 low dose cytarabine 52 Phase 2b Clinical Trial 52 cabazitaxel 52 mapatumumab 52 LIALDA 52 metaglidasen 52 Elotuzumab 52 relapsed GBM 52 Chronic lymphocytic leukemia 52 investigational therapies 52 vinca alkaloid 52 INSPIRE Trial Phase III 52 BCG refractory carcinoma 52 TORISEL 52 Brentuximab Vedotin SGN 52 pan HDAC inhibitor 52 VaD 52 Follicular Lymphoma 52 baminercept 52 idiopathic thrombocytopenic purpura ITP 52 systemic fungal infections 52 dosing cohort 52 carcinoid syndrome 52 pouchitis 52 intermittent claudication 52 Epratuzumab 52 Imprime PGG 52 unstable angina pectoris 52 venlafaxine XR 52 Triapine 52 Bortezomib 52 MabThera Rituxan 52 TG MV 52 Advanced Renal Cell 52 HER2 overexpression 52 tumors GIST 52 MPS VI 52 Fludara 52 hyperphenylalaninemia HPA due 52 oral vancomycin 52 vorinostat 52 velafermin 52 Pirfenidone 52 xanthine oxidase inhibitor 52 refractory gout 52 Complicated Skin 52 refractory myeloma 52 ECTRIMS 52 refractory anaplastic astrocytoma 52 neovascular AMD 52 TREANDA 52 Phase III randomized 52 refractory metastatic 52 C1 INH 52 severe exacerbations 52 IPL# 52 refractory DLBCL 52 PKC# 52 Tasimelteon 52 PEG IFN 52 basiliximab 52 polycythemia vera essential thrombocythemia 52 Chronic Lymphocytic Leukemia CLL 52 Vandetanib 52 Castration Resistant Prostate Cancer 52 acute promyelocytic leukemia 52 AZILECT R 52 fallopian tube carcinoma 52 ATTR 52 placebo controlled Phase 52 chronic angina 52 MIRAPEX 52 refractory chronic lymphocytic 52 Phase #/#a trial 52 cancer cachexia 52 Dacogen injection 52 temsirolimus 52 calcineurin inhibitor 52 tigecycline 52 placebo dexamethasone 52 Fibrin Pad 52 evaluable 52 ZACTIMA 52 subcutaneous formulation 52 myelodysplastic myeloproliferative diseases 52 chronic HCV infection 52 tolvaptan 52 Evoltra 52 VFEND 52 obatoclax 52 acne vulgaris 52 FOLFOX6 52 Ulcerative Colitis 52 severe psoriasis 52 YONDELIS R 52 Deforolimus 52 EXJADE 52 Pemetrexed 52 refractory epilepsy 52 hepatitis C HCV 52 acute decompensated heart 52 Acute Myeloid Leukemia 52 multicenter prospective 52 RLAI 52 hyperuricemia 52 tasocitinib 52 juvenile myoclonic epilepsy 52 terlipressin 52 knee osteoarthritis OA 52 Seliciclib 52 HRPC 52 tamibarotene 52 pheochromocytoma 52 prostate cancer CRPC 52 EFFEXOR XR 52 myeloproliferative disorders 52 visceral metastases 52 GOUT 52 pulmonary arterial hypertension PAH 52 chronic myeloid 52 invasive aspergillosis 52 IMGN# 52 FTY# 52 Crohn disease CD 52 IPX# 52 remission induction 52 Annamycin 52 evaluating REVLIMID 52 fingolimod 52 ribavirin RBV 52 Cariprazine 52 Newly Diagnosed Multiple Myeloma 52 randomized Phase IIb 52 Torisel 52 heterozygous FH 52 bipolar depression 52 Tamibarotene 52 FOLFOX4 51 Overactive Bladder 51 serum phosphate 51 histologically confirmed 51 Major Depressive Disorder 51 canakinumab 51 DLBCL 51 Myelodysplastic syndromes MDS 51 refractory angina 51 recurrent glioblastoma multiforme GBM 51 indolent lymphoma 51 SCH # 51 bone metastasis 51 ULORIC 51 Phase 2a trial 51 multiple sclerosis MS 51 eslicarbazepine acetate 51 corticosteroid dose 51 EFAPROXYN 51 HIV HCV coinfected 51 ZYBRESTAT TM 51 radiation sensitizer 51 bortezomib Velcade R 51 complete remissions 51 hematologic malignancies 51 HUMIRA adalimumab 51 gouty arthritis 51 PFO migraine 51 Severe Sepsis 51 hormone refractory prostate cancer 51 pediatric bipolar disorder 51 davunetide intranasal AL 51 cutaneous melanoma 51 ATL/TV# 51 relapsed Acute Myeloid 51 multicenter Phase III 51 neurological manifestations 51 Multicenter 51 Malignant Melanoma 51 metastatic CRPC 51 docetaxel Taxotere ® 51 BRIM3 51 phase III ACCLAIM 51 pain palliation 51 hepatocellular cancer 51 RezularTM 51 ErbB2 positive 51 anthracyclines taxanes 51 ADPKD 51 overactive bladder OAB 51 Temsirolimus 51 multicenter randomized double 51 Amigal 51 NYHA Class III 51 heavily pretreated patients 51 ARCALYST 51 gastrointestinal stromal tumors 51 Cloretazine R VNP#M 51 registrational Phase 51 rhIGF-I/rhIGFBP-3 51 macular edema 51 levodopa carbidopa 51 phase Ib 51 KIACTA ™ 51 lupus erythematosus 51 neutropenia dehydration dyspnea 51 Firazyr 51 IMC A# 51 AA amyloidosis 51 Actemra tocilizumab 51 methotrexate MTX 51 Onrigin 51 highly emetogenic 51 bevacizumab Avastin ® 51 Enzastaurin 51 relapsed refractory AML 51 KRAS mutant tumors 51 dyslipidemia 51 Lubiprostone 51 Ceflatonin R 51 davunetide 51 NUVIGIL 51 evaluable subjects 51 MMX mesalamine 51 Lenalidomide 51 CA4P 51 generalized anxiety disorder GAD 51 chronic ITP 51 haematological cancers 51 Symadex 51 refractory Hodgkin lymphoma 51 donepezil 51 Phase IIIb 51 glufosfamide 51 myeloproliferative diseases 51 BCG refractory 51 smoldering myeloma 51 Acute Coronary Syndrome 51 4mg/kg 51 paroxysmal nocturnal hemoglobinuria PNH 51 idiopathic pulmonary fibrosis IPF 51 TELINTRA 51 metastatic renal 51 subsyndromal 51 natalizumab 51 acute myeloid leukemia AML 51 Lamotrigine 51 hematologic toxicity 51 DMARD 51 Simulect 51 renal cell carcinoma 51 LY# [003] 51 docetaxel chemotherapy 51 rALLy clinical trial 51 androgen independent 51 HCV infected 51 remitting MS 51 severe plaque psoriasis 51 OHR/AVR# 51 dexanabinol 51 Psoriatic arthritis 51 prucalopride 51 rotigotine 51 AIR2 Trial 51 levodopa therapy 51 RE LY 51 advanced NSCLC 51 Chronic Lymphocytic Leukemia 51 lapatinib Tykerb 51 FTY# fingolimod 51 CTEPH 51 aripiprazole Abilify 51 VELCADE 51 symptomatic paroxysmal AF 51 briakinumab 51 DOXIL 51 Soft Tissue Sarcoma 51 Proxinium TM 51 splenectomized 51 CTAP# Capsules 51 mycophenolate mofetil 51 levetiracetam 51 Major Depressive Disorder MDD 51 Campath alemtuzumab 51 anti TNF alpha 51 gemcitabine carboplatin 51 immune thrombocytopenic purpura 51 mycosis fungoides 51 Idiopathic pulmonary fibrosis 51 chronic immune thrombocytopenic 51 MCyR 51 Dapagliflozin 51 HGS# 51 patientswith 51 multicenter randomized placebo controlled 51 Pegasys ® 51 prospective multicenter 51 oxypurinol 51 hepatitis C genotype 51 JAK inhibitor 51 dexpramipexole 51 HoFH 51 peripheral sensory neuropathy 51 LHON 51 ankylosing spondylitis 51 thromboembolic 51 prostate cancer CaP 51 severe oral mucositis 51 huN# DM1 51 hypercholesterolemia 51 IL# PE#QQR 51 macroalbuminuria 51 ATACAND 51 medically inoperable 51 RCW breast cancer 51 decitabine 51 Acute Promyelocytic Leukemia 51 STRIDE PD 51 rituximab Rituxan 51 Parkinson Disease PD 51 estramustine 51 Vidaza azacitidine 51 placebo controlled dose escalation 51 gastrointestinal GI motility disorders 51 atypical hemolytic uremic syndrome 51 Unstable Angina 51 Glioblastoma Multiforme GBM 51 ® lenalidomide 51 taxane chemotherapy 51 IIIA NSCLC 51 Yondelis ® 51 retinal vein occlusion induced 51 peginterferon alfa 2a 51 Critical Limb Ischemia CLI 51 GRN# 51 diarrhea predominant IBS 51 imatinib therapy 51 Plaque Psoriasis 51 herpetic keratitis 51 GEM OS1 51 golimumab CNTO 51 lomitapide 51 diabetic macular edema 51 COU AA 51 steroid refractory ulcerative 51 follicular lymphoma FL 51 tyrosine kinase inhibitor TKI 51 monotherapy 51 esophageal candidiasis 51 mitoxantrone 51 mucosal healing 51 OMNARIS HFA 51 acromegalic patients 51 infliximab 51 Troxatyl 51 hepatocellular carcinoma 50 allogeneic stem cell 50 Alzheimer Disease AD 50 post operative ileus 50 HP Acthar Gel repository 50 gemcitabine Gemzar ® 50 PXD# 50 certolizumab 50 thromboembolic events 50 histologies 50 ganetespib 50 tegaserod 50 Glatiramer acetate 50 Hervé Hoppenot President 50 Pramipexole 50 label dose escalation 50 metastatic colorectal cancer 50 lymphoid malignancies 50 glatiramer acetate Copaxone 50 PNP inhibitor 50 aflibercept 50 plaque psoriasis 50 evaluable patients 50 ALA PDT 50 Vectibix 50 recurrent herpes labialis 50 acute promyelocytic leukemia APL 50 TACE 50 candidemia 50 chronic idiopathic thrombocytopenic purpura 50 adjunctive ABILIFY 50 Rasagiline 50 carcinoid tumors 50 carcinoid 50 Genz # 50 Juvenile Idiopathic Arthritis 50 galantamine 50 liposomal doxorubicin 50 Bronchitol 50 antithrombotic 50 T#I [002] 50 neratinib 50 TNF inhibitor 50 follicular lymphomas 50 Arcalyst 50 imatinib Gleevec 50 gemcitabine Gemzar 50 herpes zoster shingles 50 Paraplatin ® 50 donepezil Aricept 50 stage IIIA 50 Metastatic Colorectal Cancer 50 Diabetic nephropathy 50 INVEGA ® 50 BR.# 50 Glioblastoma 50 dilated cardiomyopathy DCM 50 BCR ABL inhibitor 50 T1DM 50 Arranon 50 acetonide FA 50 cangrelor 50 atypical antipsychotic 50 diagnosed Ph + 50 null responder 50 Atiprimod 50 adjunctive therapy 50 Systemic Sclerosis 50 refractory acute myeloid 50 NOXAFIL 50 treatment naive genotype 50 anti angiogenic therapy 50 untreated multiple myeloma 50 Acute Heart Failure 50 Nocturia 50 chronic periodontitis 50 follicular lymphoma 50 nilotinib Tasigna ® 50 angiogenesis inhibitor 50 metastatic gastric 50 UPLYSO 50 failure ADHF 50 Ilaris 50 CANCIDAS 50 Ankylosing spondylitis 50 thymoma 50 zanolimumab 50 Ustekinumab 50 pimecrolimus cream 50 Keppra R 50 Actemra 50 ASCT 50 trabectedin 50 recurrent glioma 50 generation purine nucleoside 50 small lymphocytic lymphoma 50 mesalazine 50 posaconazole 50 placebo controlled clinical trials 50 ara C 50 Lennox Gastaut syndrome 50 HGS ETR1 50 mixed dyslipidemia 50 chronic myelogenous leukemia CML 50 systolic hypertension 50 dacarbazine DTIC 50 mGluR5 NAM 50 HAE 50 progressive psoriatic arthritis 50 dyslipidaemia 50 lurasidone 50 Neurodex 50 antiretroviral naïve 50 Abatacept 50 dacetuzumab 50 Halaven 50 ThermoDox R 50 stage IIIB IV 50 DMARDs 50 tiotropium 50 azacitidine 50 APEX AMI trial 50 Gemzar ® 50 pancreatic adenocarcinoma